Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Regeneron, with a consensus EPS estimate of $10.60, reflecting a -12.2% change, while revenues are expected to increase slightly by 0.7% to $3.82 billion [3][12]. Earnings Report Expectations - The earnings report is scheduled for January 30, and if the results exceed expectations, the stock may rise; conversely, missing estimates could lead to a decline [2]. - Management's commentary during the earnings call will significantly influence the sustainability of any immediate price changes and future earnings expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 4.61% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Regeneron is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +1.06%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy) [10]. - Regeneron currently holds a Zacks Rank of 1, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Regeneron exceeded the expected EPS of $9.44 by delivering $11.83, resulting in a surprise of +25.32% [13]. - Over the past four quarters, Regeneron has surpassed consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Nurix Therapeutics is expected to report a loss of $0.84 per share, with revenues projected at $17.89 million, reflecting a year-over-year increase of 34.7% [18][19]. - Nurix Therapeutics has an Earnings ESP of +38.41% and a Zacks Rank of 3 (Hold), indicating a likelihood of beating the consensus EPS estimate [20].